Article

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

2020-11-06

Abstract excerpt

<h4>Longer Abstract</h4> <h4>Background</h4> The stabilized prefusion form of the SARS-CoV-2 spike protein is produced by transient expression in Nicotiana benthamiana . The trimeric spike glycoproteins are displayed at the surface of self-assembling Virus-Like-Particles that mimic the shape and the size of the virus. The candidate vaccine (CoVLP) administered alone or with AS03 or CpG1018 adjuvants was evaluat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2696bc83-1088-544b-a90c-5fe2f29b7f4d
DOI: 10.1101/2020.11.04.20226282

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in PlantsDOI 10.1101/2020.11.04.20226282Read

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03Semantic proximity Read

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineSemantic proximity Read

Plant-produced RBD and cocktail-based vaccine candidates are highly effective against SARS-CoV-2, independently of its emerging variantsSemantic proximity Read

Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with ComorbiditiesSemantic proximity Read

First-in-Human Trial of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018Semantic proximity Read

Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particlesSemantic proximity Read

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogensSemantic proximity Read

SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic studySemantic proximity Read

Safety and immunogenicity of a recombinant DNA COVID-19 vaccine containing the coding regions of the spike and nucleocapsid proteins: Preliminary results from an open-label, phase 1 trial in healthy adults aged 19–55 yearsSemantic proximity Read

VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New VariantsSemantic proximity Read

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read

Prime hAd5 Spike + Nucleocapsid Vaccination Induces Ten-Fold Increases in Mean T-Cell Responses in Phase 1 Subjects that are Sustained Against Spike VariantsSemantic proximity Read